KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2016 - 2021)

Vertex Pharmaceuticals has reported Long-Term Debt Issuances over the past 10 years, most recently at $10.0 million for Q4 2021.

  • Quarterly results put Long-Term Debt Issuances at $10.0 million for Q4 2021, up 114.68% from a year ago — trailing twelve months through Sep 2022 was $10.0 million (down 42.06% YoY), and the annual figure for FY2021 was $22.6 million, up 69.92%.
  • Long-Term Debt Issuances for Q4 2021 was $10.0 million at Vertex Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for VRTX hit a ceiling of $30.0 million in Q4 2017 and a floor of $1.0 million in Q3 2021.
  • Median Long-Term Debt Issuances over the past 5 years was $5.3 million (2017), compared with a mean of $7.2 million.
  • Biggest five-year swings in Long-Term Debt Issuances: surged 226.5% in 2017 and later crashed 73.78% in 2018.
  • Vertex Pharmaceuticals' Long-Term Debt Issuances stood at $30.0 million in 2017, then crashed by 73.78% to $7.9 million in 2018, then rose by 14.52% to $9.0 million in 2019, then plummeted by 48.23% to $4.7 million in 2020, then surged by 114.68% to $10.0 million in 2021.
  • The last three reported values for Long-Term Debt Issuances were $10.0 million (Q4 2021), $1.0 million (Q3 2021), and $8.0 million (Q2 2021) per Business Quant data.